T1	Participants 40 153	postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer
T2	Participants 457 575	12-93, postmenopausal women with node-positive, estrogen receptor (ER)-positive or ER-negative, operable breast cancer
